VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a licensing agreement with Swiss Contract Manufacturing Organization (CMO) Lonza, securing access to Lonza’s innovative bYlok bispecific pairing technology. Financial terms of the agreement were not disclosed.
Lonza’s bYlok technology addresses the prevalent industry challenge of heavy-light chain mispairing in bispecific antibodies (BsAbs). By leveraging this technology, VIVA Biotech aims to enhance its large molecule capabilities, facilitating the design and production of high-quality BsAbs and improving overall production efficiency.- Flcube.com